Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piers Blombery

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
Blood Advances|February 17, 2018
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapySara Mastaglio, Eric Wong, Travis Perera, et al.
Pathology|October 9, 2025
Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemiaSally M Hunter, Lana Radulovic, Ella R Thompson, et al.
Annals of Hematology|February 6, 2017
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratoryRishu Agarwal, Piers Blombery, Michelle McBean, et al.
Leukemia & Lymphoma|August 16, 2021
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTENImogen Caldwell, David Byrne, Stephen Lade, et al.
Annals of Hematology|June 16, 2011
Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complicationsPiers Blombery, H Miles Prince, Leon J Worth, et al.
Kidney International Reports|December 11, 2020
Cat-Scratch Disease Masquerading as C3 GlomerulonephritisBenjamin Sutu, Shio Yen Tio, Lucy C Fox, et al.
Ejhaem|November 29, 2023
Favorable outcomes of <i>DDX41</i>-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomideIng S Tiong, William S Stevenson, Meaghan Wall, et al.
British Journal of Haematology|May 20, 2016
Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitorsKah-Lok Chan, Piers Blombery, Kate Jones, et al.
Internal Medicine Journal|May 24, 2023
Targeting the BRAF pathway in haematological diseasesMatthew J Rees, Michael Dickinson, James Paterson, et al.
Genome Biology|January 7, 2022
JAFFAL: detecting fusion genes with long-read transcriptome sequencingNadia M Davidson, Ying Chen, Teresa Sadras, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
Blood Advances|February 17, 2018
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapySara Mastaglio, Eric Wong, Travis Perera, et al.
Pathology|October 9, 2025
Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemiaSally M Hunter, Lana Radulovic, Ella R Thompson, et al.
Annals of Hematology|February 6, 2017
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratoryRishu Agarwal, Piers Blombery, Michelle McBean, et al.
Leukemia & Lymphoma|August 16, 2021
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTENImogen Caldwell, David Byrne, Stephen Lade, et al.
Annals of Hematology|June 16, 2011
Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complicationsPiers Blombery, H Miles Prince, Leon J Worth, et al.
Kidney International Reports|December 11, 2020
Cat-Scratch Disease Masquerading as C3 GlomerulonephritisBenjamin Sutu, Shio Yen Tio, Lucy C Fox, et al.
Ejhaem|November 29, 2023
Favorable outcomes of <i>DDX41</i>-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomideIng S Tiong, William S Stevenson, Meaghan Wall, et al.
British Journal of Haematology|May 20, 2016
Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitorsKah-Lok Chan, Piers Blombery, Kate Jones, et al.
Internal Medicine Journal|May 24, 2023
Targeting the BRAF pathway in haematological diseasesMatthew J Rees, Michael Dickinson, James Paterson, et al.
Genome Biology|January 7, 2022
JAFFAL: detecting fusion genes with long-read transcriptome sequencingNadia M Davidson, Ying Chen, Teresa Sadras, et al.
Pageof 16